Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
By Dr. Matthew Watson
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 12, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.
More:
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
By Dr. Matthew Watson
–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies–
See the rest here:
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
By Dr. Matthew Watson
DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO, Lisa Yañez suddenly passed away on Tuesday, May 2, 2023. The entire Aerami community mourns the loss of Lisa and extends our deepest sympathies to her family during this difficult time. Lisa possessed limitless empathy, intellect, bravery, and compassion. Lisa’s career, fueled by her endless curiosity and passion for helping others, was magnificent, but most important to her was her family, whom she loved dearly. Our thoughts are with Lisa’s family and her extensive network of friends and colleagues.
Link:
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic…
By Dr. Matthew Watson
Study Did Not Meet Primary Endpoint Study Did Not Meet Primary Endpoint
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
By Dr. Matthew Watson
NEW YORK, May 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.
View post:
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
Ocugen Provides Business Update with First Quarter 2023 Financial Results
By Dr. Matthew Watson
Conference Call and Webcast Today at 8:30 a.m. ET
Continued here:
Ocugen Provides Business Update with First Quarter 2023 Financial Results
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
By Dr. Matthew Watson
DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday, May 12, 2023. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
View post:
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
By Dr. Matthew Watson
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter
See the original post:
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time
By Dr. Matthew Watson
LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 11:30 a.m. Eastern Time. The schedule change is in order to ensure compliance with SEC disclosure requirements in light of the pending transaction with Spectrum Pharmaceuticals, Inc.
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
By Dr. Matthew Watson
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
Read the original here:
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
By Dr. Matthew Watson
-Conference call and webcast to be held at 8:30 a.m. EDT-
Read this article:
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
Alvotech S.A. Annual General Meeting to be held June 6, 2023
By Dr. Matthew Watson
The Annual General Meeting of Alvotech S.A. will be held on Tuesday 6 June 2023, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg.
Visit link:
Alvotech S.A. Annual General Meeting to be held June 6, 2023
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
By Dr. Matthew Watson
LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 25th European Congress of Endocrinology (ECE), which is being held May 13-16 in Istanbul, Turkey, and at the 2023 Endocrine Society Meeting (ENDO), which is being held June 15-18 in Chicago, Illinois. These presentations cover both of Amolyt’s development programs, eneboparatide entering Phase 3 for hypoparathyroidism and AZP-3813 entering Phase 1 for acromegaly.
Read more from the original source:
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
By Dr. Matthew Watson
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the 60th ERA Congress from June 15 – 18, 2023, both virtual and live in Milan, Italy. The five accepted abstracts will be delivered as three focused orals (digital poster with 3-minute presentation), one free communication (10-minute live oral presentation) and one moderated oral presentation (6-slide presentation).
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
By Dr. Matthew Watson
JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the first quarter ended March 31, 2023.
Link:
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
Pardes Biosciences Reports First Quarter 2023 Financial Results
By Dr. Matthew Watson
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023.
Continued here:
Pardes Biosciences Reports First Quarter 2023 Financial Results
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
By Dr. Matthew Watson
RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.
Follow this link:
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
By Dr. Matthew Watson
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on May 3, 2023.
Continue reading here:
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries
By Dr. Matthew Watson
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries.
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
By Dr. Matthew Watson
ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highlighting data from non-clinical and clinical studies of deucrictibant at the 13th C1-inhibitor Deficiency and Angioedema Workshop, being held from May 4-7, 2023, in Budapest, Hungary.
View original post here:
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop